🚨 NEW STOCK — V2 aluminium Peptide Pens have landed. Five colours, 40 units only.
AVERON logoAVERON

Tirzepatide

APPROVED MEDICINE

Approved as Mounjaro and Zepbound in several countries, including Indonesia. Research-grade material is not the branded product.

At a glance. A once-weekly dual agonist of the GIP and GLP-1 receptors with one of the largest trial programmes in its class. Sold by AVERON as TZP GLP2.

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

What it is

Tirzepatide is a synthetic peptide that activates two incretin hormone receptors: GIP and GLP-1. Incretins are gut hormones released after eating that increase insulin release, slow stomach emptying and act on appetite centres in the brain. By acting on both receptors, tirzepatide was designed to produce stronger effects than a GLP-1 agonist alone.

It was developed by Eli Lilly and is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.

What researchers study it for

Type 2 diabetes, obesity, obstructive sleep apnoea in people with obesity, fatty liver disease, heart failure and cardiovascular outcomes.

What the research shows

SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity, or overweight with at least one related condition, and without diabetes. Over 72 weeks, average weight change was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, compared with −3.1% on placebo.

SURMOUNT-5, published in the same journal in 2025, was the first head-to-head trial against semaglutide. Over 72 weeks, average weight change was −20.2% with tirzepatide compared with −13.7% with semaglutide. See tirzepatide vs semaglutide.

A separate trial programme, called SURPASS, established its effects on blood sugar in type 2 diabetes.

What it does not do, and what is not known

  • Research-grade material is not Mounjaro or Zepbound. It has not been manufactured or tested to the standards of the registered medicine.
  • It is not a stimulant or a fat burner. Its effect comes from reduced appetite and slower digestion.
  • Weight tends to return after it is stopped. Trials that stopped treatment observed substantial regain.
  • It does not specifically protect muscle. A share of weight lost in trials was lean mass.
  • Its approved uses are specific. Approval for diabetes and weight management does not extend to any other purpose.

Adverse effects reported in research

The most common were gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain, most frequent while the dose was being increased. Less common but more serious risks listed in the prescribing information include pancreatitis, gallbladder disease and hypoglycaemia when combined with certain diabetes medicines.

The US label carries a boxed warning about thyroid C-cell tumours, based on findings in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Regulatory and anti-doping status

Regulatory: Approved by the US FDA as Mounjaro (2022) and Zepbound (2023), and approved in the European Union. In Indonesia, BPOM granted marketing authorisation for tirzepatide in February 2026 for type 2 diabetes, with weight management added in July 2026.

Anti-doping: Not on WADA's Prohibited List. GLP-1 receptor agonists are included in WADA's Monitoring Program, which tracks patterns of use without prohibiting them.

At AVERON

Supplied as research-grade material under the name TZP GLP2, 10 mg.

Independent lab report: 123404_M8KKGXSBJ7LZ

Frequently asked questions

It is the same molecule. Mounjaro and Zepbound are registered medicines made and tested to pharmaceutical standards. Research-grade tirzepatide is not those products.

Yes. BPOM authorised it in February 2026 for type 2 diabetes and added weight management in July 2026.

An average of 20.9% at the highest dose after 72 weeks, compared with 3.1% on placebo.

No. GLP-1 receptor agonists are on WADA's Monitoring Program, not the Prohibited List.

Thyroid C-cell tumours observed in rodents. Whether this applies to humans is not established, but the drug is contraindicated in people with certain thyroid cancer histories.

Doses mentioned on this page are the arms of published trials, given to describe their results. They are not guidance.

Sources

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022;387:205–216. Link
  2. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 2025. Link
  3. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. FDA. Link
  4. Badan Pengawas Obat dan Makanan (BPOM). BPOM. BPOM. Link
  5. World Anti-Doping Agency. Monitoring Program. WADA. Link

Related pages

...